Annual report pursuant to Section 13 and 15(d)

Related Party Transactions - Additional Information (Detail)

v3.8.0.1
Related Party Transactions - Additional Information (Detail)
5 Months Ended 8 Months Ended 9 Months Ended 12 Months Ended 16 Months Ended 20 Months Ended
Jul. 24, 2017
USD ($)
$ / shares
shares
Jul. 20, 2017
shares
Jul. 19, 2017
shares
Jul. 18, 2017
USD ($)
$ / shares
shares
Mar. 07, 2017
USD ($)
Sep. 30, 2015
USD ($)
$ / shares
shares
May 18, 2015
USD ($)
Dec. 31, 2017
USD ($)
$ / shares
Dec. 31, 2015
USD ($)
shares
Sep. 30, 2016
USD ($)
Dec. 31, 2017
USD ($)
$ / shares
Dec. 31, 2016
USD ($)
NotesPayable
$ / shares
Dec. 31, 2016
USD ($)
$ / shares
Dec. 31, 2016
USD ($)
$ / shares
Jul. 31, 2017
USD ($)
Related Party Transaction [Line Items]                              
Accounts payable, related parties                       $ 829,000 $ 829,000 $ 829,000  
Debt conversion, converted instrument, amount                 $ 2,000,000            
Common stock, par value | $ / shares               $ 0.001     $ 0.001 $ 0.001 $ 0.001 $ 0.001  
Accrued salaries                       $ 1,028,000 $ 1,028,000 $ 1,028,000  
Common Stock                              
Related Party Transaction [Line Items]                              
Debt conversion, converted instrument, shares issued | shares                 4,500            
Ricanto, Ltd [Member]                              
Related Party Transaction [Line Items]                              
Consulting fees incurred, related parties                   $ 100,000 $ 0        
Related party consulting agreement, date of termination                     Aug. 01, 2017        
Accounts payable, related parties       $ 600,000       $ 0     $ 0 600,000 600,000 600,000  
Shares issued to related party for services | shares       475                      
Shares issued to related party, par value | $ / shares       $ 0.01                      
Ricanto, Ltd [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock                              
Related Party Transaction [Line Items]                              
Conversion of each outstanding share of Achieve common stock , shares converted | shares       359.3053                      
Number of shares post-conversion | shares       170,670                      
Chief Executive Officer [Member]                              
Related Party Transaction [Line Items]                              
Accounts payable, related parties               0     0        
Notes payable, related parties                       $ 200,000 200,000 200,000  
Number of notes payable | NotesPayable                       2      
Notes payable, rate of interest                       3.50%      
Notes payable repayment period                       1 year      
Outstanding principal, included in shareholder loans                       $ 200,000 200,000 200,000  
Accrued interest owed to related party               0     0 3,000 3,000 3,000  
Salary paid                           0  
Chief Executive Officer [Member] | Accrued Compensation [Member]                              
Related Party Transaction [Line Items]                              
Salary paid               400,000              
Accrued salaries                       700,000 700,000 700,000  
Accrued salaries, common stock shares issued | shares     238                        
Percentage of common stock issued in settlement of accrued salaries     50.00%                        
Percentage of cash payment in settlement of accrued salaries     50.00%                        
Chief Executive Officer [Member] | Convertible Notes Payable [Member]                              
Related Party Transaction [Line Items]                              
Shares issued to related party, par value | $ / shares $ 0.01                            
Debt conversion, converted instrument, amount $ 200,000                            
Debt conversion, converted instrument, shares issued | shares 146                            
Chief Executive Officer [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock                              
Related Party Transaction [Line Items]                              
Conversion of each outstanding share of Achieve common stock , shares converted | shares 359.3014   359.3025                        
Number of shares post-conversion | shares 52,458   85,514                        
Lender                              
Related Party Transaction [Line Items]                              
Accounts payable, related parties               0     0 700,000 700,000 700,000  
Notes payable, related parties         $ 20,000                    
Notes payable, rate of interest         3.50%                    
Notes payable repayment period         1 year                    
Accrued interest owed to related party               0     0 35,000 35,000 35,000  
Debt conversion, converted instrument, amount $ 800,000                            
Debt conversion, converted instrument, shares issued | shares 586                            
Common stock, par value | $ / shares $ 0.01                            
Lender | Convertible Promissory Note [Member]                              
Related Party Transaction [Line Items]                              
Notes payable, related parties             $ 2,700,000                
Notes payable, rate of interest             3.50%                
Debt conversion, converted instrument, amount           $ 2,000,000                  
Debt conversion, converted instrument, shares issued | shares           4,500                  
Common stock, par value | $ / shares           $ 0.01                  
Lender | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock                              
Related Party Transaction [Line Items]                              
Conversion of each outstanding share of Achieve common stock , shares converted | shares 359.3052                            
Number of shares post-conversion | shares 1,827,426                            
Chief Financial Officer [Member]                              
Related Party Transaction [Line Items]                              
Accounts payable, related parties               0     0        
Accrued interest owed to related party               0     0        
Salary paid                         0    
Chief Financial Officer [Member] | Accrued Compensation [Member]                              
Related Party Transaction [Line Items]                              
Salary paid               200,000              
Accrued salaries                       $ 300,000 $ 300,000 $ 300,000  
Accrued salaries, common stock shares issued | shares   127                          
Percentage of common stock issued in settlement of accrued salaries   50.00%                          
Percentage of cash payment in settlement of accrued salaries   50.00%                          
Chief Financial Officer [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock                              
Related Party Transaction [Line Items]                              
Conversion of each outstanding share of Achieve common stock , shares converted | shares   359.2992                          
Number of shares post-conversion | shares   45,631                          
Michelle Griffin [Member] | OncoGenex Pharmaceuticals, Inc [Member]                              
Related Party Transaction [Line Items]                              
Termination fee payable                             $ 600,000
Michelle Griffin [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Accrued Liabilities Other [Member]                              
Related Party Transaction [Line Items]                              
Accounts payable, related parties               $ 0     $ 0